Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Koziorowska A et al. | 2018 | - | 50/60 Hz, low frequency, magnetic field | - |
Zeng Y et al. | 2017 | intact cell/cell culture, primary hippocampal neurons from rat embryos | 50/60 Hz, magnetic field | 2 mT |
Solek P et al. | 2018 | - | 50/60 Hz, magnetic field | - |
Sun C et al. | 2018 | intact cell/cell culture, mouse embryonic fibroblasts (wild type and <i>Atm</i>-deficient) | 50/60 Hz, magnetic field | 2 mT |
Rajendra P et al. | 2012 | intact cell/cell culture, sheep primary lymphocytes | 50/60 Hz, magnetic field | 5–100 µT |
Koziorowska A et al. | 2017 | intact cell/cell culture, 143B (human osteosarcoma cell line), BJ (human fibroblast cell line) | 50/60 Hz, magnetic field | 2–6 mT |
Shahbazi-Gahrouei D et al. | 2014 | intact cell/cell culture, human adipose-derived mesenchymal stem cells | 50/60 Hz, magnetic field | 0.5–1 mT |
Asadian N et al. | 2021 | intact cell/cell culture, rat bone marrow-derived mesenchymal stem cells | 50/60 Hz, magnetic field | 400 µT |
Colciago A et al. | 2021 | intact cell/cell culture, HEI-193 cells (human vestibular schwannoma cell line derived from a NF2 patient) | 50/60 Hz, magnetic field | 0.1 T |
Heidari S et al. | 2021 | intact cell/cell culture, human adenocarcinoma gastric cancer cell line (AGS) | 50/60 Hz, magnetic field | 0.2–2 mT |
Moya-Gómez A et al. | 2023 | intact cell/cell culture, BV2 cells (immortalized murine microglial cell line), SHSY5Y cells, (immortalized human neuroblastoma cell line), primary mouse microglia and neurons, animal, mongolian gerbils <i>(Meriones unguiculatus)</i> (stroke model) | 50/60 Hz, magnetic field | - |
Yahyapour R et al. | 2023 | intact cell/cell culture, T98 (glioma cell line) | 50/60 Hz, magnetic field, also other exposures without EMF | - |
Falone S et al. | 2017 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | 50/60 Hz, magnetic field, co-exposure | 0.1–1 mT |
Sztafrowski D et al. | 2023 | intact cell/cell culture, <i>Candida albicans</i> (strains CAF2-1 and CAF4-2) | 50/60 Hz, magnetic field, co-exposure, also other exposures without EMF | - |
Balbaa AO et al. | 2019 | - | 50/60 Hz, magnetic field, electric field, co-exposure | - |
Koziorowska A et al. | 2017 | intact cell/cell culture, human neonatal fibroblast BJ | 50/60 Hz, magnetic field, low frequency, signals/pulses | 2.5 mT |
Amiri M et al. | 2018 | intact cell/cell culture, human glioblastoma cell line (U-87) | 50/60 Hz, static magnetic field, magnetic field, co-exposure, also other exposures without EMF | - |
García-Minguillán López O et al. | 2019 | - | RF field, magnetic field, low frequency, 50/60 Hz | - |
Ramstad S et al. | 2000 | bacterium, <i>Propionibacterium acnes</i> | electric field, magnetic field, 50/60 Hz | 200 µT |
Saikia J et al. | 2019 | isolated bio./chem. substance, beta-amyloid protein | electric field, magnetic field, 50/60 Hz, static electric field | - |
Schimmelpfeng J et al. | 1997 | intact cell/cell culture, SV40-swiss-3T3 cells (mouse fibroblast cell line) and HL-60 cells (human acute myeloid leukaemia cell line) | magnetic field, 50/60 Hz | 2 mT |
Fiorio R et al. | 1993 | intact cell/cell culture, V79 (Chinese hamster fibroblast cells) | magnetic field, 50/60 Hz | 200 µT |
Pieroni L et al. | 1998 | intact cell/cell culture, virus/bacteriophages, murine B lymphocytes and T lymphocytes infected with a murine retrovirus (Mo-MLV) | magnetic field, 50/60 Hz | 1 mT |
Loberg LI et al. | 2000 | intact cell/cell culture, MCF-7, ZR-75-1, T-47D, and MDA-MB-231 (breast cancer cell line) and normal human breast epithalial cells | magnetic field, 50/60 Hz | 1 mT |
Strasak L et al. | 2002 | bacterium, <i>Escherichia coli</i> | magnetic field, 50/60 Hz | 2.7–10 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.